Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response [0.03%]
Joy Li,Jordan Fredette,Nagendra Dhanikonda et al.
Joy Li et al.
Introduction: Enfortumab vedotin (EV), alone or in combination with pembrolizumab (EV/P) are established treatment for metastatic urothelial carcinoma (mUC). Patients who discontinue EV after achieving a complete or parti...
GLP-1RAs Use and Postoperative Outcomes in T2DM Patients Undergoing Radical Nephrectomy [0.03%]
GLP-1RA的使用对接受根治性肾切除术的2型糖尿病患者预后的影响
Sam Kwon,Diego Gonzalez,Fiona Wardrop et al.
Sam Kwon et al.
Introduction: To determine the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and postoperative outcomes, including 90-day complications and overall survival, in patients with type 2 diabetes m...
The Contemporary Pattern of Radical Cystectomy in the Treatment of High-Grade Non-Muscle Invasive Bladder Cancer [0.03%]
当代根治性膀胱切除术治疗高级别非肌层浸润性膀胱癌的模式
Parsa Iranmahboub,Priya Dave,Joshua Levine et al.
Parsa Iranmahboub et al.
Introduction: Radical cystectomy (RC) remains the most effective treatment for high-grade non-muscle invasive bladder cancer (HG NMIBC) with high-risk features or after failed bladder preservation. Yet, utilization varies...
Treatment and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer by Race, Initial Diagnosis, and Family History: Results From the TRUMPET Registry [0.03%]
基于TRUMPET登记的转移性去势抵抗性前列腺癌患者的治疗及转归：按人种、初始诊断及家族史分类
Lawrence Karsh,Clara Hwang,James Symanowski et al.
Lawrence Karsh et al.
Introduction: To better understand how treatment patterns, clinical outcomes, health-related quality of life, and healthcare resource utilization are impacted by initial prostate cancer diagnosis, prostate cancer family h...
Treatment Type and Mortality for Black Versus White Patients With Muscle-Invasive Bladder Cancer [0.03%]
针对肌层浸润性膀胱癌患者的治疗类型及黑人和白人的死亡率差异研究
Peyton A Skupin,Shan Wu,Oluwaseun Orikogbo et al.
Peyton A Skupin et al.
Introduction: Black patients with muscle-invasive bladder cancer have higher mortality compared with White patients. This study evaluated the association of treatment type on overall and bladder cancer-specific survival a...
The Prognostic Role of HER2 Expression in Patients With Non-Muscle-Invasive Bladder Cancer [0.03%]
HER2表达在非肌层浸润性膀胱癌患者中的预后作用
Xuejian Yang,Lingkai Cai,Chenghao Wang et al.
Xuejian Yang et al.
Background/objectives: The available risk stratification models used to predict the prognosis of non-muscle-invasive bladder cancer (NMIBC) are not efficient enough. The research focused on assessing the relationship betw...
Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC) [0.03%]
无生存获益的PSA暂时性抑制：卡巴珠单抗联合卡铂治疗转移性去势抵抗性前列腺癌（mCRPC）的现实世界有效性比较研究
Ahmad Basharat,Muhammad Shaheer Mannan,Muhammad Raffey Shabbir et al.
Ahmad Basharat et al.
Background: Platinum-based intensification has emerged as a potential strategy in metastatic castration-resistant prostate cancer (mCRPC). However, its real-world effectiveness remains uncertain. ...
Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) [0.03%]
镥[177Lu]维匹福韦特四肽治疗后患者中转移性去势抵抗性前列腺癌（mCRPC）的治疗模式和生存结果：真实世界队列研究
Ben Tran,Tanya Dorff,Madeline Richey et al.
Ben Tran et al.
Introduction: To evaluate treatments and survival in patients with metastatic castration-resistant prostate cancer (mCRPC) who received subsequent treatment after Lutetium 177 vipivotide tetraxetan (LuPSMA) in the real-wo...
From Target Plausibility to Analytical Recovery: Digital PCR-Based Uromonitor and the Platform Question in Urinary Tumor DNA Surveillance [0.03%]
从目标合理性到分析恢复：基于数字PCR的尿液监测仪和尿液肿瘤DNA监测平台问题
Matthias May,José Rubio-Briones,Maximilian Burger et al.
Matthias May et al.
Real-World Treatment Patterns and Predictors of Treatment Allocation in Metastatic Non-Clear Cell Renal Cell Carcinoma: A National Cancer Database Analysis [0.03%]
转移性非透明细胞肾细胞癌的现实世界治疗模式及治疗分配预测因素：来自动脉国家癌症数据库的分析结果
Andrea Cosenza,Zhiyu Qian,David-Dan Nguyen et al.
Andrea Cosenza et al.
Introduction: Non-clear cell renal cell carcinoma (nccRCC) comprises heterogeneous cancers historically managed using evidence extrapolated from clear cell RCC. Current guidelines support histology-guided treatment, but r...